ZYTIGA® (abiraterone acetate)

Efficacy & Safety

Efficacy & Safety
  • Final analysis of the pivotal Phase 3 study.
  • Co-primary and secondary endpoints data.
  • Established safety and tolerability profile.
  • Discontinuation criteria noted in the COU-AA-302 Study.

Dosing & Monitoring

Dosing & Monitoring
  • ZYTIGA® recommended dosage and administration.
  • Dose modification guidelines.
  • Patient monitoring considerations and schedule. 

Support & Resources

Support & Resources
  • Comprehensive access support for your patients. 
  • Identifying cost support options according to your patient’s needs.
  • Helpful resources for you, your patients, and their loved ones.

Janssen Oncology

The Janssen Commitment

For more than 30 years, Janssen Biotech, Inc., has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.